NR1H4 and Hepatic steatosis: Combination therapies are also being explored, such as a phase II study combining semaglutide with the FXR agonist cilofexor and the ACC inhibitor firsocostat, which showed greater improvements in hepatic steatosis and metabolic biomarkers compared to semaglutide alone.